论文部分内容阅读
据德国先灵公司人员称,在过去几年,德国先灵公司已转变成研究、探索及开发的公司。 “探索”意味着先灵把需求新技术、合作伙伴放在重要位置,这与公司在专业治疗及诊断领域成为市场先驱的最终目标相一致。 先灵公司在造影剂、生殖类产品领域已处于领先地位,并准备在其它领域(例如肿瘤学方面)有所发展。先灵公司人员称,该公司将在今后有所发展而不是昙花一现。 据先灵公司预测,其临床治疗产品的销售额能从1996年的13亿德国马克增加至2005年的25亿(其中包括在发展中的新产品:抗癌、心血管及中枢神经系统新药)。
According to German Schering Company personnel, in the past few years, Schering AG has transformed into a research, exploration and development company. “Exploration” means that Schering takes the new technologies and partners needed to position in an important position, which is in line with the company’s ultimate goal of becoming a market pioneer in the field of professional treatment and diagnosis. Schering AG has taken a leading position in the fields of contrast agents and reproductive products and is preparing to develop in other fields such as oncology. Schering Company personnel said that the company will develop in the future rather than a flash in the pan. According to Schering’s prediction, the sales of its clinical therapeutic products can increase from 1.3 billion deutsche marks in 1996 to 2.5 billion in 2005 (including new products under development: new drugs for cancer, cardiovascular and central nervous system). .